With bribery fines behind it, GSK brings back bonuses for sales staff
British drugmaker GlaxoSmithKline (LSE: GSK) has reintroduced its bonus program for sales staff, to “better recognize and reward individual effort.”
The firm was prompted to ban bonuses for its salespeople in 2012 after it was hit by a $3 billion fine for bribing doctors to write additional prescriptions for its products. Legislation such as the US Sunshine Act also compelled a change to practices.
GSK was also forced to fire 110 staff in China in 2014, and pay almost half a billion dollars in fines, following an investigation which found instances of bribery. The firm also published a statement of apology to the Chinese government and its people at that time.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze